Hyperaesthesia adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 8,142 adverse event reports that record the MedDRA preferred term Hyperaesthesia. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 242 reports in the 12 months to June 2026 and 279 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,286 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 242 (under 0.1%) record this term. Reports for patients aged 45 to 64 were 29.2% of the reports that record this term and 20% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 103 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Hyperaesthesia name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetaminophen		92
Acetaminophen Oxycodone Hydrochloride		36
Acetaminophen Tramadol		38
Actemra	Interleukin-6 receptor antagonist	128
Alprazolam	Benzodiazepine	36
Amitriptyline		25
Aubagio	Pyrimidine synthesis inhibitor	27
Avonex	Interferon beta	181
Baclofen	gamma-Aminobutyric acid-ergic agonist	47
Bupivacaine	Amide local anesthetic	35
Buprenorphine	Partial opioid agonist	67
Butrans	Partial opioid agonist	43
Capecitabine	Nucleoside metabolic inhibitor	44
Carboplatin	Platinum-based drug	32
Chlorhexidine		26
Ciprofloxacin	Fluoroquinolone antibacterial	64
Clonidine	Central alpha-2 adrenergic agonist	37
Cosentyx	Interleukin-17A antagonist	51
Cyclobenzaprine	Muscle relaxant	37
Cymbalta		65
Dexamethasone	Corticosteroid	46
Diazepam	Benzodiazepine	42
Diclofenac	Nonsteroidal anti-inflammatory drug	46
Diclofenac sodium	Nonsteroidal anti-inflammatory drug	36
Dilaudid	Opioid agonist	75
Duloxetine	Serotonin and norepinephrine reuptake inhibitor	34
Dupixent	Interleukin-4 receptor alpha antagonist	57
Eliquis	Factor Xa inhibitor	44
Enbrel	Tumor necrosis factor blocker	266
Fentanyl	Opioid agonist	302
Fentanyl citrate	Opioid agonist	41
Forteo	Parathyroid hormone analog	39
Gabapentin	Anti-epileptic agent	120
Gilenya	Sphingosine 1-phosphate receptor modulator	47
Herceptin	HER2/neu receptor antagonist	52
Human immunoglobulin g	Human immunoglobulin G	25
Humira		319
Hydrocodone bitartrate and acetaminophen	Opioid agonist	67
Hydromorphone		208
Hydromorphone hcl		50
Hydromorphone hydrochloride	Opioid agonist	69
Ibrance	Kinase inhibitor	62
Ibuprofen	Nonsteroidal anti-inflammatory drug	56
Inflectra	Tumor necrosis factor blocker	29
Inlyta	Kinase inhibitor	38
Kadcyla		38
Ketamine		46
Ketoprofen	Nonsteroidal anti-inflammatory drug	48
Levaquin		35
Lidocaine	Amide local anesthetic	32
Losec		32
Lyrica		153
Methadone	Opioid agonist	154
Methotrexate	Folate analog metabolic inhibitor	113
Methotrexate sodium	Folate analog metabolic inhibitor	27
Morphine	Opioid agonist	261
Morphine sulfate	Opioid agonist	216
Mounjaro	GLP-1 receptor agonist	39
MS Contin	Opioid agonist	39
Nexavar	Kinase inhibitor	53
Nexium	Proton pump inhibitor	27
Niaspan		30
Ocrevus	CD20-directed cytolytic antibody	40
Omeprazole	Proton pump inhibitor	37
Oxaliplatin	Platinum-based drug	42
Oxycodone	Opioid agonist	176
Oxycodone and acetaminophen	Opioid agonist	47
Oxycodone hydrochloride	Opioid agonist	178
OxyContin	Opioid agonist	116
Ozempic	GLP-1 receptor agonist	35
Pantoprazole	Proton pump inhibitor	41
Pegasys	Interferon alpha	52
Percocet	Opioid agonist	39
Perjeta	HER2/neu receptor antagonist	41
Prednisone	Corticosteroid	45
Pregabalin		96
Prolia	RANK ligand inhibitor	55
Ramipril	Angiotensin converting enzyme inhibitor	43
Rebif	Interferon beta	34
Remicade	Tumor necrosis factor blocker	32
Repatha	PCSK9 inhibitor	25
Revlimid	Thalidomide analog	37
Ribavirin	Nucleoside analog antiviral	47
Rituxan	CD20-directed cytolytic antibody	27
Rituximab	CD20-directed cytolytic antibody	36
Rosuvastatin	HMG-CoA reductase inhibitor	27
Sertraline	Serotonin reuptake inhibitor	56
Simponi	Tumor necrosis factor blocker	26
Stivarga	Kinase inhibitor	29
Sutent	Kinase inhibitor	128
Synthroid	l-Thyroxine	25
Tarceva		49
Tecfidera		86
Tramadol		90
Tramadol hydrochloride	Opioid agonist	41
Trastuzumab	HER2/neu receptor antagonist	37
Tysabri	Integrin receptor antagonist	130
Wegovy	GLP-1 receptor agonist	74
Womens Rogaine Unscented	Arteriolar vasodilator	27
Xeljanz	Janus kinase inhibitor	48
Xeloda	Nucleoside metabolic inhibitor	124
Xolair	Anti-IgE	33
Zometa		28

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 57 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Hyperaesthesia name, in order of name
Class	Reports with this term
Acetylcholine release inhibitor	32
Alkylating drug	28
Amide local anesthetic	99
Androgen receptor inhibitor	29
Angiotensin converting enzyme inhibitor	45
Anti-epileptic agent	178
Anti-IgE	42
Antimalarial	27
Aromatase inhibitor	35
Arteriolar vasodilator	29
Atypical antipsychotic	79
Benzodiazepine	176
beta-Adrenergic blocker	27
Bisphosphonate	26
CD20-directed cytolytic antibody	127
CD52-directed cytolytic antibody	25
Central alpha-2 adrenergic agonist	48
Corticosteroid	235
Factor Xa inhibitor	76
Fluoroquinolone antibacterial	90
Folate analog metabolic inhibitor	140
gamma-Aminobutyric acid-ergic agonist	58
GLP-1 receptor agonist	185
HER2/neu receptor antagonist	130
Histamine-1 receptor antagonist	35
HMG-CoA reductase inhibitor	87
Human immunoglobulin G	36
Integrin receptor antagonist	132
Interferon alpha	52
Interferon beta	225
Interleukin-17A antagonist	55
Interleukin-4 receptor alpha antagonist	61
Interleukin-6 receptor antagonist	137
Janus kinase inhibitor	62
Kinase inhibitor	546
l-Thyroxine	30
Microtubule inhibitor	32
Muscle relaxant	41
Nonsteroidal anti-inflammatory drug	273
Nucleoside analog antiviral	53
Nucleoside metabolic inhibitor	191
Opioid agonist	1,940
Parathyroid hormone analog	39
Partial opioid agonist	122
PCSK9 inhibitor	29
Phosphodiesterase 5 inhibitor	25
Platinum-based drug	90
Programmed death Receptor-1 blocking antibody	25
Proton pump inhibitor	145
Pyrimidine synthesis inhibitor	35
RANK ligand inhibitor	76
Serotonin and norepinephrine reuptake inhibitor	71
Serotonin reuptake inhibitor	146
Sphingosine 1-phosphate receptor modulator	49
Tetracycline-class drug	27
Thalidomide analog	50
Tumor necrosis factor blocker	405

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Hyperaesthesia, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Hyperaesthesia
Age	Reports	Share
Under 2	53	0.7%
2 to 11	88	1.1%
12 to 17	125	1.5%
18 to 44	1,747	21.5%
45 to 64	2,378	29.2%
65 to 74	879	10.8%
75 and over	470	5.8%
Age not given	2,402	29.5%

Sex of the patient in the reports that record Hyperaesthesia
Sex	Reports	Share
Female	4,983	61.2%
Male	2,671	32.8%
Unknown or not given	488	6%

Age and sex are as the report gives them. 61.6% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Hyperaesthesia: adverse event reports that record this term. https://reportedreactions.com/reaction/hyperaesthesia/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Hyperaesthesia mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page